絞り込み

16645

広告

新型ウイルス肺炎 北朝鮮国営航空 外国人観光客は乗せない対応

中国で新型のコロナウイルスによるものとみられる肺炎への感染が広がっている問題を受けた北朝鮮の動きです。北朝鮮国営のコリョ(高麗)航空はNHKの取材に対し、北京か...

  1. 新型ウイルス肺炎 マカオでも感染者を初確...
  2. 調達情報 中小企業のための女性活躍推進事...
  3. 調達情報 民間人材サービスの活用検討事業...
  4. 書店水槽に「ぴろぴろの何か」 絶滅危惧ド...

ニュース一覧

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling.

著者 Nishiya N , Murai M , Hosoda A , Yonezawa H , Omori N
Pharmaceuticals (Basel).2019 Nov 07 ; 12(4):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)

Full Text Sources

Miscellaneous

Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival of the therapies. Therefore, controlling adverse effects not only facilitates treatment continuation but also increases clinical benefits. In this study, we proposed a novel strategy for reducing EGFR-tyrosine kinase inhibitor (TKI)-induced adverse effects in nontumorous organs by repositioning approved medicines using a zebrafish model. We developed a model system for evaluating chemical quenchers of afatinib, a clinically available irreversible EGFR-TKI, by scoring the inhibition of afatinib-induced hyperformation of lateral line neuromasts in zebrafish larvae. Bucillamine, an antirheumatic drug, was identified as an afatinib quencher in the zebrafish system and inhibited TKI activity in vitro. In addition, bucillamine restored EGFR autophosphorylation and downstream signaling in afatinib-treated A431 cells. Thus, topical bucillamine is a potential reliever of irreversible EGFR-TKI-induced skin rash. The zebrafish model can be applied to a screening for quenchers of other anti-EGFR-targeting therapies, including reversible TKIs and biologics.
PMID: 31703435 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード